Doravirine - Merck & Co
Alternative Names: MK-1439; MK-1439-019; Pifeltro; PIFELTROLatest Information Update: 04 Dec 2025
At a glance
- Originator Merck & Co
- Developer Merck & Co; National Institute of Allergy and Infectious Diseases
- Class Antiretrovirals; Benzonitrile; Chlorinated hydrocarbons; Fluorinated hydrocarbons; Pyridones; Small molecules; Triazoles
- Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Yes - HIV-1 infections
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed HIV-1 infections
Most Recent Events
- 04 Dec 2025 Launched for HIV-1 infections (In the elderly, In children, In adults) in USA (PO), prior to December 2025 (Merck & Co website, December 2025)
- 04 Dec 2025 Launched for HIV-1 infections in China (PO), prior to December 2025 (Merck & Co website, December 2025)
- 04 Dec 2025 Launched for HIV-1 infections in Japan (PO), prior to December 2025 (Merck & Co website, December 2025)